Bristol-Myers Squibb (BMY) Receives FDA Approval for Expanded Daklinza Indication in Genotype 1, 3 HCV
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) announced today that Daklinza™ (daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been approved ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
